Prot #17403: A Randomized, Open Label, Multicenter Phase 2/3 Study to Evaluate the Efficacy and Safety of Rogaratinib (BAY 1163877) Compared to Chemotherapy in Patients with FGFR-Positive Locally Advanced or Metastatic Urothelial Carcinoma who Have Receiv